| Project/Area Number |
10670878
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | KANSAI MEDICAL UNIVERSITY |
|---|
Principal Investigator |
HARIMA Keizoo Kansai Med. Univ. Radiology, Associate Professor, 医学部, 助教授 (20121973)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HARIMA Yoko Kansai Med. Univ. Radiology, Assistant Professor, 医学部, 講師 (80140276)
|
|---|
| Project Period (FY) |
1998 – 1999
|
| Project Status |
Completed (Fiscal Year 1999)
|
| Budget Amount *help |
¥3,100,000 (Direct Cost: ¥3,100,000)
Fiscal Year 1999: ¥1,200,000 (Direct Cost: ¥1,200,000)
Fiscal Year 1998: ¥1,900,000 (Direct Cost: ¥1,900,000)
|
|---|
| Keywords | Cervical carcinoma / Transcatheter arterial chemoembolization / Tumor suppressor gene / Predictive marker |
|---|
| Research Abstract |
Purpose : The ratio of Bcl-2 to Bax expression determines survival or death following an apoptotic stimulus. In order to establish a new predictor of the outcome of treatment for human cervical carcinoma, we investigated the relationship between the expressions of the Bax and Bcl-2 proteins and the response to chemoembolization using CDDP comparing pre- and after treatment.
Methods : A total of 40 patients with histologically proven carcinoma of the uterine cervix, including three with recurrent cervical stump carcinomas, were treated with definitive chemoembolization using CDDP. The presence of mutations in exons 5-8 of the p53 gene was analyzed by a single-strand conformation polymorphism analysis and DNA sequencing.
Results : Thirty six patients were found to have wild-type p53, and the remaining four had mutant p53. P53 gene did not correlated with the response to chemoembolization and survival. The Bax and Bcl-2 protein expressions prior to chemoembolization did not correlate with response or survival.
However, the Bax and Bcl-2 protein expressions after chemoembolization correlated with both response or survival. Bax-positive tumors showed significantly better responses than the Bax-negative tumors after chemoembolization (P=0.02). In contrast, the Bcl-2-positive tumors showed significantly poorer responses than the Bcl-2-negative tumors after chemoembolization (P=0.02). Increased Bax expression after chemoembolization was found to be correlated with good survival (P=0.04). In contrast, increased Bcl-2 expression after such chemoembolization was correlated with poor survival (P=0.002).
Conclusion : The levels of Bax and Bcl-2 expression after chemoembolization are useful prognostic markers in patients with human cervical carcinoma.
|
